| Date | Time | Source | Headline | Symbol | Company |
| 05/17/2024 | 3:00PM | iHub Newswire | FeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements | | |
| 05/09/2024 | 4:30PM | Edgar (US Regulatory) | Form SD - Specialized disclosure report | NYSE:BIO | Bio Rad Laboratories Inc |
| 05/08/2024 | 4:38PM | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NYSE:BIO | Bio Rad Laboratories Inc |
| 05/08/2024 | 4:31PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NYSE:BIO | Bio Rad Laboratories Inc |
| 05/08/2024 | 2:25PM | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NYSE:BIO | Bio Rad Laboratories Inc |
| 05/07/2024 | 4:18PM | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:BIO | Bio Rad Laboratories Inc |
| 05/07/2024 | 4:15PM | Business Wire | Bio-Rad Reports First-Quarter 2024 Financial Results | NYSE:BIO | Bio Rad Laboratories Inc |
| 05/01/2024 | 9:00AM | Business Wire | Bio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare Conference | NYSE:BIO | Bio Rad Laboratories Inc |
| 04/26/2024 | 8:30AM | Business Wire | Bio-Rad Announces Life Science Group Management Changes | NYSE:BIO | Bio Rad Laboratories Inc |
| 04/18/2024 | 9:00AM | Business Wire | Bio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 | NYSE:BIO | Bio Rad Laboratories Inc |
| 04/11/2024 | 5:30PM | GlobeNewswire Inc. | Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay | NYSE:BIO | Bio Rad Laboratories Inc |
| 04/10/2024 | 4:15PM | Business Wire | Bio-Rad’s Chief Operating Officer Andrew Last to Retire | NYSE:BIO | Bio Rad Laboratories Inc |
| 03/20/2024 | 8:30AM | Business Wire | Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer | NYSE:BIO | Bio Rad Laboratories Inc |
| 02/22/2024 | 4:30PM | Business Wire | Bio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access Day | NYSE:BIO | Bio Rad Laboratories Inc |
| 02/15/2024 | 4:15PM | Business Wire | Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results | NYSE:BIO | Bio Rad Laboratories Inc |
| 01/24/2024 | 5:00PM | Business Wire | Bio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 | NYSE:BIO | Bio Rad Laboratories Inc |
| 01/02/2024 | 4:15PM | Business Wire | Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare Conference | NYSE:BIO | Bio Rad Laboratories Inc |
| 10/26/2023 | 4:15PM | Business Wire | Bio-Rad Reports Third-Quarter 2023 Financial Results | NYSE:BIO | Bio Rad Laboratories Inc |
| 10/05/2023 | 8:30AM | Business Wire | Bio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023 | NYSE:BIO | Bio Rad Laboratories Inc |
| 08/28/2023 | 4:15PM | Business Wire | Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference | NYSE:BIO | Bio Rad Laboratories Inc |
| 08/03/2023 | 4:15PM | Business Wire | Bio-Rad Reports Second-Quarter 2023 Financial Results | NYSE:BIO | Bio Rad Laboratories Inc |
| 07/26/2023 | 4:15PM | Business Wire | Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement | NYSE:BIO | Bio Rad Laboratories Inc |
| 07/20/2023 | 4:30PM | Business Wire | Bio-Rad Announces New Share Repurchase Program | NYSE:BIO | Bio Rad Laboratories Inc |
| 07/10/2023 | 4:30PM | Business Wire | Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023 | NYSE:BIO | Bio Rad Laboratories Inc |
| 07/10/2023 | 9:00AM | Business Wire | Bio-Rad Publishes Corporate Sustainability Report for 2022 | NYSE:BIO | Bio Rad Laboratories Inc |
| 06/15/2023 | 5:13PM | Edgar (US Regulatory) | Report of Proposed Sale of Securities (144) | NYSE:BIO | Bio Rad Laboratories Inc |
| 06/07/2023 | 11:32AM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NYSE:BIO | Bio Rad Laboratories Inc |
| 06/06/2023 | 5:59PM | Edgar (US Regulatory) | Report of Proposed Sale of Securities (144) | NYSE:BIO | Bio Rad Laboratories Inc |
| 06/05/2023 | 8:46AM | Edgar (US Regulatory) | Current Report Filing (8-k) | NYSE:BIO | Bio Rad Laboratories Inc |
| 06/01/2023 | 8:00AM | Business Wire | Bio-Rad to Present Company Overview at Jefferies Healthcare Conference | NYSE:BIO | Bio Rad Laboratories Inc |